Literature DB >> 16333769

Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?

Stephan Rüegg1, Monique Lehky Hagen, Ursula Hohl, Ludwig Kappos, Peter Fuhr, Martina Plasilov, Hansjakob Müller, Karl Heinimann.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset. OPMD is among the few triplet repeat diseases/ polyalanine (poly(A)) expansion diseases for which the function of the mutated gene is quite well established. The disease is characterised by slowly progressive bilateral ptosis, dysphagia and proximal limb weakness, appearing after the age of 40 years. Prevalence and incidence of OPMD are low, but the disease occurs all over the world. The pedigrees of two Swiss kindred have been previously reported in Switzerland. In the last 2 years, accumulation of newly diagnosed cases in North-West Switzerland have been observed, which suggests that OPMD may be more prevalent than previously thought. Primary care providers, opthalmologists and neurologists that are alert for the almost specific combination of clinical signs, together with the availability of reliable genetic testing may help to recognise currently undiagnosed patients. They can advance knowledge and the characterisation of the OPMD population in Switzerland. Since the number of disorders linked to poly(A) expansions is growing rapidly, the study of OPMD may contribute to the understanding of a large group of other developmental and degenerative diseases. On the basis of a patient with "classical" OPMD, this review summarises the clinical, therapeutic, epidemiological, pathomechanistic and genetic aspects of OPMD, provides practical information about the differential diagnosis of OPMD, and presents a survey of different investigational methods.

Entities:  

Mesh:

Year:  2005        PMID: 16333769     DOI: 2005/39/smw-11221

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  13 in total

Review 1.  Approach to a patient with blepharoptosis.

Authors:  Samira Yadegari
Journal:  Neurol Sci       Date:  2016-06-21       Impact factor: 3.307

2.  Cricopharyngeal dilatation for the long-term treatment of dysphagia in oculopharyngeal muscular dystrophy.

Authors:  Joseph G Manjaly; Peter G Vaughan-Shaw; Oliver T Dale; Susan Tyler; Jonathan C R Corlett; Roger A Frost
Journal:  Dysphagia       Date:  2011-07-30       Impact factor: 3.438

3.  Gene diagnosis of oculopharyngeal muscular dystrophy in a Chinese family by a GeneScan method.

Authors:  Pan You; Qilin Ma; Tao Tao
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 4.  PABPN1: molecular function and muscle disease.

Authors:  Ayan Banerjee; Luciano H Apponi; Grace K Pavlath; Anita H Corbett
Journal:  FEBS J       Date:  2013-05-24       Impact factor: 5.542

5.  Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a Chinese population.

Authors:  Jingli Shan; Bin Chen; Pengfei Lin; Duoling Li; Yuebei Luo; Kunqian Ji; Jinfan Zheng; Yun Yuan; Chuanzhu Yan
Journal:  Neuromolecular Med       Date:  2014-10-05       Impact factor: 3.843

6.  Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis.

Authors:  Luciano H Apponi; Sara W Leung; Kathryn R Williams; Sandro R Valentini; Anita H Corbett; Grace K Pavlath
Journal:  Hum Mol Genet       Date:  2009-12-24       Impact factor: 6.150

7.  Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review.

Authors:  Benedikt G H Schoser
Journal:  Clin Ophthalmol       Date:  2007-03

Review 8.  Oculopharyngeal muscular dystrophy as a paradigm for muscle aging.

Authors:  Yotam Raz; Vered Raz
Journal:  Front Aging Neurosci       Date:  2014-11-10       Impact factor: 5.750

9.  PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.

Authors:  Pascale Richard; Capucine Trollet; Teresa Gidaro; Laurence Demay; Guy Brochier; Edoardo Malfatti; Fernando Ms Tom; Michel Fardeau; Pascal Lafor; Norma Romero; Marie-Laure Martin-N; Guilhem Sol; Xavier Ferrer-Monasterio; Jean Lacau Saint-Guily; Bruno Eymard
Journal:  J Neuromuscul Dis       Date:  2015-06-04

10.  Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle.

Authors:  Luciano H Apponi; Anita H Corbett; Grace K Pavlath
Journal:  Skelet Muscle       Date:  2013-10-01       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.